According to Zhito Finance APP, leading company in the field of clinical-stage allogeneic cell therapy and gene drugs, Poseida therapeutics (PSTX.US) announced it will be acquired by Roche Holdings for approximately $1.5 billion in total equity value. The acquisition includes $9.00 per share in cash and additional non-tradable contingent value rights (CVRs), which may provide shareholders with up to an additional $4.00 per share in cash payments upon achieving specific milestones. The entire trade is expected to be completed smoothly in the first quarter of 2025. Poseida will continue to advance its non-viral CAR-T therapy and gene drug development as part of Roche's pharmaceutical division.

Since 2022, Poseida has been collaborating with Roche to develop ready-to-use CAR-T cell therapy for patients with hematologic malignancies. This acquisition not only marks Poseida's official inclusion into the Roche group but also indicates that both parties will achieve deeper progress in the field of allogeneic cell therapy.

Roche's Chief Medical Officer Levi Garraway stated, "With the existing successful collaboration foundation with Poseida, this acquisition will undoubtedly drive further breakthroughs in our allogeneic cell therapy efforts."

Poseida President and CEO Dr. Kristin Yarema also expressed enthusiasm for the collaboration, stating, "We are excited to deepen our cooperation with Roche to advance our product lines and future projects together. Roche's global strength in late-stage development and commercialization will undoubtedly help to translate the potential of allo CAR-T for patients around the world."